Памид

Quick links to important sections

Памид

Treatment option: Hypertension

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Памид

What is Памид? (Overview)

Property Description
Active ingredient Indapamide
Form Oral Tablet
Pharmacological class Diuretic (Thiazide-like) / Antihypertensive
Common use Control of High Blood Pressure and Edema
Origin Synthetic Compound

What is Памид and How is it Classified?

Памид (Pamid) is a prescription medication used primarily for the long-term management of elevated blood pressure, or hypertension, and to manage fluid retention (edema). It contains the single active ingredient, Indapamide.

This medicine is classified as an antihypertensive agent and belongs to the pharmacological group known as diuretics, specifically a thiazide-like diuretic. Its dual mechanism, which both reduces fluid volume and helps relax blood vessels, is clinically recognized for supporting sustained control of blood pressure. It is important to know that Indapamide is a synthetic compound, meaning its structure is chemically derived rather than being extracted from natural sources.

Composition, Form, and Origin of Памид

The core active component of the medication is the manufactured substance Indapamide. Памид is supplied in its finished form as an oral tablet and is intended to be swallowed. The oral form is designed for ease of use in chronic therapeutic regimens.

As a single product, the tablet contains only Indapamide alongside standard inactive excipients (fillers) necessary for its stability and proper absorption. The precise composition of the synthetic compound ensures a consistent and reliable dosage in every pill.

What is the General Purpose of Taking Памид?

The general therapeutic purpose of Памид is the sustained reduction of elevated blood pressure. This reduction is crucial because it alleviates strain on the heart and arteries, which is a key modifiable risk factor for cardiovascular disease.

The medicine is also used to reduce edema, or swelling caused by the pooling of excess fluid in tissues. In essence, its primary goal is to help maintain a healthy blood pressure profile to protect vital organs, contributing to overall cardiovascular longevity.

Regulatory References

  1. NIH ClinicalTrials.gov: Поиск исследований Индапамида

What side effects are possible with Памид?

Official Safety Profile and Possible Adverse Effects

The safety profile of Памид (Indapamide) is organized according to the frequency and system-organ class, as documented in official government regulatory documents. The most frequently observed safety characteristic is the risk of electrolyte disturbances, particularly hypokalaemia (low plasma potassium), which is classified as common.

Frequency Classification of Adverse Reactions

Adverse reactions are categorized by frequency of occurrence:

Frequency Category Examples of Documented Reactions
Common (≥ 1/100) Hypokalaemia, Maculopapular rash, General weakness (asthenia)
Uncommon (≥ 1/1,000) Nausea, Vomiting, Hyponatraemia (low sodium)
Rare (≥ 1/10,000) Vertigo, Headache, Gout
Very Rare (< 1/10,000) Arrhythmia, Agranulocytosis, Thrombocytopenia

Serious and Contextual Safety Information

Regulatory documentation highlights several serious adverse reactions, although they are rare. These include the risk of hepatic encephalopathy in individuals with pre-existing severe hepatic impairment and potentially life-threatening cardiac rhythm disorders like Torsades de pointes, which is strongly associated with hypokalaemia.

Official labels also define population-specific restrictions. Памид is contraindicated in cases of severe renal failure, severe hepatic impairment, and pre-existing, uncorrected hypokalaemia. For certain effects, like an increase in blood urea and plasma creatinine, regulatory documents note that they are typically observed at the start of treatment due to initial fluid loss. Use in the pediatric population is not recommended as safety and efficacy have not been established.

Overdose and Emergency Response

A documented overdose of Памид (Indapamide) primarily manifests due to severe volume depletion and critical fluid and electrolyte imbalances. Recognized clinical signs described in official regulatory labels include profound low blood pressure (hypotension), accompanied by systemic symptoms such as drowsiness, confusion, intense thirst, and dry mouth. Gastrointestinal distress, including nausea and vomiting, along with muscle cramps and reduced urine output (oliguria), are also documented manifestations. Severe cases are associated with potentially life-threatening outcomes such as respiratory depression, cardiac dysrhythmias, and critically low levels of sodium and potassium (hyponatremia and hypokalemia), which require immediate correction.

In the event of a suspected or confirmed overdose, the official regulatory guidance is to seek emergency medical attention immediately and contact the nearest hospital emergency department. This immediate action is mandated because treatment is strictly symptomatic and supportive, as regulatory sources confirm that no specific antidote is known for Indapamide. Supportive measures officially described include continuous monitoring for electrolyte and fluid imbalances, potential stomach content evacuation, and circulatory support to manage severe hypotension. Official labeling notes that elderly females may be particularly susceptible to developing severe hyponatremia and hypokalemia.

Therapeutic Uses of Памид

Памид is indicated for the management of symptoms associated with excessive stomach acid. Its main uses focus on acute symptomatic relief and the long-term support for chronic acid-related disorders. Common clinical scenarios include addressing occasional heartburn, indigestion, and acid regurgitation. It is used to assist patients dealing with conditions such as gastroesophageal reflux disease (GERD), duodenal ulcer, and peptic ulcer disease. The goal of treatment is to support comfort and assist in the management of acid-related irritation in the upper gastrointestinal tract.

“The management of acid reflux symptoms is an essential step in supporting patient comfort and quality of life.”

Quick Fact: Relief for Persistent Discomfort Памид may assist in the management of recurring symptoms, such as bloating and upper abdominal pain, that are linked to chronic acid exposure.

Eligibility and Restrictions for Use

Who can and cannot use Памид?

The eligibility profile for Памид (Indapamide) is strictly defined by regulatory authorities and is determined by pre-existing conditions, organ function, and patient demographics.

Absolute Contraindications

Use of the medicine is formally contraindicated and must be avoided in populations with:

  • Known hypersensitivity to Indapamide or any sulfonamide-derived drug.
  • Severe renal impairment (creatinine clearance below 30 ml/min) or Anuria.
  • Severe impairment of liver function or hepatic encephalopathy.
  • Pre-existing Hypokalaemia (abnormally low blood potassium levels).

Restricted and Not Recommended Use

The medicine is not recommended for the pediatric population (children and adolescents) because regulatory safety and efficacy data have not been established. Use is also officially contraindicated or not recommended during pregnancy and lactation.

Conditional Eligibility

The medicine may be used with caution and strict monitoring in certain adult populations. This includes patients with mild-to-moderate renal or hepatic impairment, Diabetes Mellitus, Gout/Hyperuricemia, or Systemic Lupus Erythematosus (SLE). Older adults may be treated if their renal function is normal or only minimally impaired.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory authorities classify specific combinations with Памид (Indapamide) based on documented interaction patterns that affect the co-administered substance's exposure or potentiate pharmacodynamic risks.

Official Interaction Restrictions

Classification Interacting Substance Regulatory Rationale (Outcome)
Contraindicated Lithium Indapamide significantly reduces the renal clearance of lithium, leading to elevated plasma concentrations and high risk of toxicity.
Contraindicated Mizolastine Increased risk of severe ventricular arrhythmia (Torsades de Pointes) linked to potential Indapamide-induced hypokalemia.

Documented Pharmacodynamic and Exposure Interactions

Interactions often involve the drug's effect on electrolyte balance. Co-administration with Digitalis Glycosides increases the risk of toxicity, as the reduction in serum potassium enhances the effects of the glycoside. The interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the effectiveness of Indapamide's antihypertensive and diuretic actions.

Co-administration with other potassium-losing agents, such as systemic Corticosteroids or Amphotericin B (IV), is officially documented as increasing the risk of severe hypokalemia due to additive effects. Furthermore, interactions with Alcohol may potentiate the risk of orthostatic hypotension. A special regulatory note highlights that interactions leading to hypokalemia carry a greater risk of precipitating hepatic encephalopathy in patients with documented hepatic impairment.

Mechanism of Action

Selective Modulation of Serotonin Receptors

This drug acts primarily by binding to the 5- HT2A serotonin receptors as a high-affinity inverse agonist. This interaction effectively modulates the intrinsic activity of the receptor, thereby influencing specific molecular signaling pathways associated with 5- HT2A receptor activity.

Targeted Interference in Neural Signaling

The drug's mechanism involves a targeted suppression of molecular cascades that are normally triggered by the 5- HT2A receptor. By selectively halting these early molecular steps, it adjusts the signaling dynamics within specific neural pathways and restricts the downstream effects of elevated mediator activity, resulting in modified physiological feedback.

Modulating Dopaminergic Independence

This mechanism exhibits high selectivity for the 5- HT2A receptor, showing minimal interaction with dopamine left( D2 ight) receptors. This focused action engages only the mechanisms that regulate overactive serotonergic processes without broadly affecting the pathways controlling motor function, influencing the subsequent functional properties of the drug.

Dosage and Administration Information

Памид (Famotidine) is officially administered via the oral route (tablet or suspension) for general use and the intravenous (IV) route for short-term use in hospitalized patients who cannot tolerate oral medication. The medicine may be taken with or without food and, when prescribed once daily, is often scheduled for administration at bedtime. OTC use is officially constrained to a maximum duration of 14 days.

Administration Focus Administration Details
Standard Adult Dosing Typically 20 mg or 40 mg once or twice daily, depending on the specific gastrointestinal condition being managed. The maximum oral dose for pathological hypersecretory conditions is 160 mg every six hours.
Dose Adjustments Adjustment is necessary for adult patients with moderate to severe renal impairment (creatinine clearance < 60 mL/ min), which requires either a 50% dose reduction or an extension of the dosing interval. Pediatric dosing is weight-based.
Preparation Rules The oral suspension must be shaken vigorously for 5 to 10 seconds prior to measuring the dose. IV administration requires slow injection over at least 2 minutes or infusion over 15 to 30 minutes after appropriate dilution.

Treatment regimens are often duration-limited; for instance, ulcer healing protocols typically run for up to eight weeks, while maintenance use for duodenal ulcers can be prescribed for up to one year. The instructions structure a precise protocol for administration, quantity, and duration, ensuring consistent use within the defined therapeutic limits.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Памид (Indapamide)


The research base for Памид (Indapamide) primarily relies on large-scale Randomized Controlled Trials (RCTs) and systematic reviews, particularly for its use in addressing high blood pressure (hypertension). These studies evaluated patient populations, tracking not only changes in blood pressure measurements but also observing patterns of serious long-term events, including stroke and myocardial infarction (heart attack). Findings describe patterns related to measured changes in blood pressure, and research explored outcomes monitoring physiological strain on the heart muscle.

Evidence also exists for fluid retention (edema), derived from smaller comparative trials and clinical assessments. This research was evaluated in patients experiencing swelling, often associated with conditions like congestive heart failure. Findings describe patterns related to measured changes in fluid balance and fluid removal. The evidence quality for this indication varies compared to the robust, multi-year trials conducted for hypertension.

Dedicated, long-term prospective outcome trials focused on patient cohorts with a prior history of stroke or Transient Ischemic Attack (TIA). These studies tracked and reported patterns related to the incidence of recurrent stroke over several years.

Across these indications, a key limitation is that the most definitive trials, which track long-term cardiovascular outcomes, often observed patients taking Памид as part of a combination therapy with another drug. This means the independent role of Памид for all outcomes is not fully isolated in those specific trials. While data are established for specific subgroups like older adults (80 years and over), data for other comorbidity-defined patient populations remain limited.

Frequently Asked Questions (FAQ)

Common questions about Памид (FAQ)

Q: Does the time of day matter when using Памид?

A: Yes, regulatory administration instructions recommend using the tablet once per 24 hours. Official guidance suggests that it be taken preferably in the morning because of its diuretic (fluid removal) effects. The recommended morning use is based on its diuretic effects, which may prevent disruption to sleep if taken later in the day.

Q: How quickly does Памид start to work?

A: Official information describes the action of Памид as progressive. While the initial effects may start relatively soon, the maximum reduction in blood pressure may not be fully achieved until several months after beginning therapy. The intended use of the medicine is for the long-term management of chronic conditions.

Q: Is it normal to feel tired after taking Памид?

A: According to official adverse reaction lists, general weakness, also known as asthenia, is classified as a common side effect of Памид. Other related effects such as fatigue and lethargy are also documented. Individuals with concerns about this common effect can discuss it with their healthcare professional.

Q: What happens if I miss a scheduled use of Памид?

A: Official consumer information advises that if a scheduled dose is missed, you should skip that dose. Official consumer information directs users to continue with the next scheduled dose at the usual time. It is specifically advised not to take a double dose to compensate for the one you missed.

Q: Are there any long-term effects associated with Памид?

A: Since Памид is used for the long-term management of chronic conditions, official documents note that certain physiological changes may persist during therapy. Official documents note that monitoring for potential changes to electrolyte levels (such as potassium), blood sugar concentrations, and uric acid concentrations is part of the long-term use of the medicine.

Q: Can I take vitamins or supplements while using Памид?

A: Regulatory documents describe potential interactions between Памид and certain supplements. For example, official warnings note that combining it with Vitamin D may lead to elevated blood calcium levels. Official guidance suggests informing a healthcare professional about all vitamins and herbal supplements being used.

Q: How long is Памид typically used?

A: For the control of high blood pressure, Памид is indicated for chronic, ongoing use, as high blood pressure is typically a condition requiring continuous treatment. There is no specific maximum duration limit defined in regulatory documents for the continuous long-term management of chronic conditions.

Q: What are the main findings from the clinical trials of Памид?

A: Clinical trials indicate that the medicine is effective in reducing blood pressure and may help reduce left ventricular hypertrophy (enlargement of the heart muscle). Official research overviews highlight that a key limitation in some definitive studies is that the drug was often evaluated as part of a combination therapy with other medicines.

Q: Is Памид the same as other drugs that treat similar conditions?

A: The active ingredient in Памид, Indapamide, is classified by regulatory bodies as an antihypertensive (a blood pressure-lowering agent). More specifically, it belongs to the group of thiazide-like diuretics. This classification is used to distinguish its mechanism from other drugs prescribed for high blood pressure.

Q: What should I do if I notice an unusual reaction after using Памид?

A: In the event of a serious or unexpected reaction, official reporting guidelines from health authorities (such as the FDA’s MedWatch program) encourage patients and consumers to voluntarily report these adverse events. This process helps regulatory bodies monitor the overall safety profile of the medicine.

Q: Will Памид cause weight changes?

A: Official adverse reaction lists mention both weight loss and unusual weight gain or loss as effects that have been documented in clinical studies. These weight changes are noted as having an unknown or less common incidence.

Q: Can I stop using Памид suddenly?

A: Since the medicine is used to manage a chronic condition like high blood pressure, official consumer information advises that it should not be stopped suddenly. Official information states that discontinuing the medicine is generally reserved for consultation with a healthcare professional.

Q: Is Памид known to cause problems with sleep?

A: Official regulatory documents list insomnia (difficulty falling or staying asleep) and nervousness as documented side effects of the drug. Insomnia and nervousness are documented in the official safety profile as recognized reactions.

Q: What happens to Памид in the body after it is used?

A: Official documents describe the pharmacokinetic properties (what the body does to the drug). They indicate that Памид is rapidly absorbed and extensively broken down (metabolized) by the liver. The majority of the drug and its byproducts are then eliminated from the body through the kidneys and the gastrointestinal tract.

Q: Are there specific laboratory tests needed when using Памид?

A: Yes, official documents describe the need for specific monitoring due to the known risks associated with the medicine. Official documents describe the need for monitoring serum electrolytes (like potassium), as well as creatinine and BUN levels. This testing is especially important during the first few months after starting use.

Q: Why is it important to tell my healthcare provider about all my current medicines before starting Памид?

A: Regulatory documents detail the necessity of discussing current medicines because Памид has documented interactions with other medicines, which are detailed in regulatory documents. Specifically, the drug can increase the risk of toxicity from medicines like Lithium or enhance the effects of certain heart rhythm drugs, particularly due to its effect on electrolyte balance.

How should Памид be stored and disposed of?

How to Store and Dispose of Памид (Indapamide)

Official regulatory guidelines define specific conditions for storing and discarding Памид (Indapamide) to ensure product stability and safety.

Storage Requirements

Памид oral tablets must be stored at room temperature, typically 20 C to 25 C (68 F to 77 F), and must be kept from freezing. The medication should be protected from excess heat, moisture, and direct light. Always store the tablets in their original container and ensure the container is tightly closed.

For child safety, the medicine must be stored out of the sight and reach of children at all times.

Disposal Instructions

Do not use the tablets after the expiry date printed on the packaging. Unused or expired tablets must be disposed of in accordance with local regulations.

To prevent environmental contamination, the product must not be flushed down the toilet, thrown into regular household trash, or allowed to enter the sewer system or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Памид found in:

A-Z Index: